14 January, 2026
The American Diabetes Association (ADA) has published its Standards of Care in Diabetes—2026, with evidence-based updates that reflect advances in diabetes technology, treatment and holistic management strategies for people living with diabetes and those at risk. These widely respected guidelines aim to support better health outcomes and more personalised care worldwide.
The ADA’s Standards of Care in Diabetes are regarded as a global benchmark for healthcare professionals, researchers, policymakers and people living with diabetes. Updated annually, they summarise the most current scientific evidence to guide decision-making in prevention, diagnosis and treatment across the full spectrum of diabetes and intermediate hyperglycaemia (or prediabetes). The 2026 edition builds on this foundation with notable shifts towards more inclusive and person-centred recommendations.
Embracing technology early and inclusively
One of the most prominent changes in the 2026 Standards concerns diabetes technology. Continuous glucose monitoring (CGM) is now recommended at the time of diagnosis and at any stage thereafter for anyone who could benefit from it as part of their diabetes management. This represents a broader approach that encourages early use of technology to support glucose awareness and improve outcomes.
In addition, the updated guidance removes previous prerequisites for initiating continuous subcutaneous insulin infusion or automated insulin delivery (AID) systems. This means that people living with diabetes may be able to access these technologies sooner, based on their individual needs and preferences, rather than waiting until specific criteria are met.
The revisions also explicitly acknowledge the value of open-source AID systems and the role of integrated digital health tools with coaching support, reflecting the growing diversity of options that support self-management.
Supporting medication strategies for diverse needs
The 2026 update includes important refinements in guidance on glucose-lowering medications and obesity pharmacotherapy. Individualisation is emphasised, so that treatment plans take into account personal health goals, tolerability and overall well-being. Newly added sections offer guidance on treating obesity in people with type 1 diabetes, and on medication use for people with chronic kidney disease, including those on dialysis.
In recognising that many glucose-lowering therapies also confer benefits beyond glycaemic control, the Standards now include broader discussion of impacts on cardiovascular, kidney and liver health. This holistic framing supports clinicians and people living people with diabetes to make informed choices that align with a person’s overarching health priorities.
Refreshing nutrition and weight-management guidance
Nutrition remains a cornerstone of diabetes care, and the 2026 Standards offer guidance on eating patterns with evidence to prevent type 2 diabetes and support overall health. The Mediterranean-style diet and carbohydrate-focused approaches, among others, are included for their practical
